 |
Contact Us Sitemap |
 |
|
 |
|
|
ZADAXIN® HCV MarketHBV MarketCancer |
 |
In a completed phase 3 trial, ZADAXIN produced a sustained seroconversion* in 20% of patients and did not cause any serious side-effects. A patient is typically considered to be cured of the virus if a sustained seroconversion is achieved.
Separate studies show pegylated interferon is effective in eliminating the virus, producing a seroconversion in 32% of patients. Lamivudine and adefovir dipivoxil are effective in suppressing the virus but are not considered a cure. These therapies produce a seroconversion in 16% and 12% of patients, respectively. Additionally, studies show that prolonged use of lamivudine can cause serious viral mutations and eventually lead to drug resistance.
Site design by Formative